Table 1.
Association between APLN expression and clinicopathological features in the TCGA cohort.
| Characters | Level | Low expression of APLN | High expression of APLN | p Value |
|---|---|---|---|---|
| n | 152 | 152 | ||
| N stage (%) | N0 | 75 (68.2%) | 58 (69.9%) | 0.924 |
| N1 | 35 (31.8%) | 25 (30.1%) | ||
| M stage (%) | M0 | 63 (96.9%) | 53 (86.9%) | 0.049a,b |
| M1 | 2 (3.1%) | 8 (13.1%) | ||
| Clinical stage (%) | Stage I | 92 (62.6%) | 70 (46.7%) | 0.006 a |
| Stage II–IV | 55 (37.4%) | 80 (53.3%) | ||
| Radiation therapy (%) | No | 73 (48.0%) | 49 (32.2%) | 0.007 a |
| Yes | 79 (52.0%) | 103 (67.8%) | ||
| Primary therapy outcome (%) | CR | 99 (88.4%) | 82 (78.1%) | 0.129 b |
| PD | 8 (7.1%) | 14 (13.3%) | ||
| PR | 4 (3.6%) | 4 (3.8%) | ||
| SD | 1 (0.9%) | 5 (4.8%) | ||
| Race (%) | Asian | 15 (11.2%) | 5 (4.0%) | 0.054 b |
| Black or African American | 12 (9.0%) | 18 (14.4%) | ||
| White | 107 (79.9%) | 102 (81.6%) | ||
| Histological type (%) | Adenosquamous | 29 (19.1%) | 23 (15.1%) | 0.446 |
| Squamous cell carcinoma | 123 (80.9%) | 129 (84.9%) | ||
| Histologic grade (%) | G1 | 11 (7.7%) | 7 (5.4%) | 0.120 b |
| G2 | 78 (54.5%) | 57 (44.2%) | ||
| G3 | 54 (37.8%) | 64 (49.6%) | ||
| G4 | 0 (0.0%) | 1 (0.8%) | ||
| Menopause status (%) | Peri | 15 (12.9%) | 10 (8.7%) | 0.230 |
| Post | 45 (38.8%) | 37 (32.2%) | ||
| Pre | 56 (48.3%) | 68 (59.1%) | ||
| PIK3CA status (%) | Mut | 40 (27.8%) | 42 (29.6%) | 0.837 |
| WT | 104 (72.2%) | 100 (70.4%) | ||
| Age (%) | ≤50 | 91 (59.9%) | 95 (62.5%) | 0.724 |
| >50 | 61 (40.1%) | 57 (37.5%) |
CR: complete response; Mut: mutant type; PD: progressive disease; PR: partial response; SD: stable disease; WT: wild type.
a
Statistically significant.
b
Fisher’s exact test.